Impact of Previous HPV Infection and CD4 T-Cell Levels on Immune Responses to a Three-Dose Nonavalent HPV Vaccine in Individuals with HIV Undergoing ART - Top-Institutions - MDSpire

Impact of Previous HPV Infection and CD4 T-Cell Levels on Immune Responses to a Three-Dose Nonavalent HPV Vaccine in Individuals with HIV Undergoing ART

  • By

  • Eeva Tortellini

  • Mariasilvia Guardiani

  • Anna Carraro

  • Lorenzo Ansaldo

  • Sara Corazza

  • Sara Giovanna De Maria

  • Silvia Garattini

  • Mirko Barresi

  • Valeria Belvisi

  • Maria Antonella Zingaropoli

  • Federica Dominelli

  • Carmen Falvino

  • Fabio Mengoni

  • Alessandro Tavelli

  • Cristina Giambi

  • Claudio Maria Mastroianni

  • Cosmo Del Borgo

  • Raffaella Marocco

  • Miriam Lichtner

  • December 24, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • HIV Research
    • Vaccine Development

  • #2

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • HIV/AIDS Clinical Research

  • #3

    University of North Carolina at Chapel Hill
    University of North Carolina at Chapel Hill

    Chapel Hill, NC

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • HIV Research

  • #4

    University of Washington
    University of Washington

    Seattle, WA

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • HIV Clinical Research

  • #5

    Imperial College London
    Imperial College London

    London, N/A

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • HIV Research
    • Vaccine Development

Original Source(s)

Impact of Previous HPV Infection and CD4 T-Cell Levels on Immune Responses to a Three-Dose Nonavalent HPV Vaccine in Individuals with HIV Undergoing ART

  • by Eeva Tortellini, Mariasilvia Guardiani, Anna Carraro, Lorenzo Ansaldo, Sara Corazza, Sara Giovanna De Maria, Silvia Garattini, Mirko Barresi, Valeria Belvisi, Maria Antonella Zingaropoli, Federica Dominelli, Carmen Falvino, Fabio Mengoni, Alessandro Tavelli, Cristina Giambi, Claudio Maria Mastroianni, Cosmo Del Borgo, Raffaella Marocco, Miriam Lichtner

  • December 24, 2025

Related Content

Clinical characteristics and antibody responses to Omicron variants among pregnant women in China during the December 2022–April 2023 COVID-19 pandemic wave

FDA Expands ASCENIV Pediatric Use

Label change follows completion of required pediatric evaluation and updates prior age restrictions for treatment eligibility.

Preclinical evaluation of a multi-epitope mRNA vaccine platform for broad and durable SARS-CoV-2 protection